RPL19B Antibody

What is RPL19B and how does it differ from RPL19?

RPL19B is a ribosomal protein that forms part of the 60S ribosomal subunit. It belongs to the L19E family of ribosomal proteins. While RPL19 is the general designation used in mammals (including humans, mice, and rats), yeast species express paralogous forms designated as RPL19A and RPL19B. These paralogs share similar functions but may have specialized roles in particular cellular processes. In Saccharomyces cerevisiae (baker's yeast), RPL19B is specifically encoded by the gene YBL027W, while in humans the corresponding protein is simply designated RPL19 .

The protein has a calculated molecular weight of 23 kDa, though it typically appears at approximately 28 kDa in Western blot analyses due to post-translational modifications .

How are RPL19B antibodies generated and what host organisms are commonly used?

RPL19B antibodies are typically generated by immunizing host animals with either:

• Recombinant full-length RPL19B protein

• Synthetic peptide fragments corresponding to specific regions of RPL19B

• RPL19B fusion proteins (e.g., Ag6371)

Host organisms commonly used include:

• Rabbits (most common for polyclonal antibodies)

• Mice (for monoclonal antibodies)

The host selection impacts specificity, with rabbit polyclonal antibodies being most common due to their robust immune response and ability to recognize multiple epitopes .

What are the optimal conditions for using RPL19B antibodies in Western blotting?

For optimal Western blotting with RPL19B antibodies, follow these methodological guidelines:

Critical methodological notes:

• Heat samples to 95-100°C in reducing sample buffer for complete denaturation

• Include protease inhibitors during sample preparation to prevent degradation

• When examining tissue samples, thorough homogenization is essential

• For low abundance detection, consider using enhanced chemiluminescence substrates

How should RPL19B antibodies be utilized for immunohistochemistry (IHC) applications?

For successful IHC with RPL19B antibodies:

• Sample preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) tissues show reliable results

  • Fresh frozen sections also work with appropriate fixation

  • Human and mouse brain tissues are validated positive controls

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval (pressure cooker or microwave) for 15-20 minutes

• Antibody dilution and incubation:

  • Dilution range: 1:20-1:200 (optimize for each lot)

  • Incubate overnight at 4°C for best signal-to-noise ratio

  • Use appropriate blocking with serum matched to secondary antibody species

• Detection systems:

  • DAB (3,3'-diaminobenzidine) for brightfield microscopy

  • Fluorophore-conjugated secondary antibodies for fluorescence microscopy

• Counterstaining:

  • Hematoxylin for nuclear morphology in brightfield

  • DAPI for nuclear visualization in fluorescence microscopy

What immunofluorescence protocols produce optimal results with RPL19B antibodies?

For high-quality immunofluorescence with RPL19B antibodies:

• Cell preparation:

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1-0.5% Triton X-100 in PBS for 5-10 minutes

  • Validated cell line: HeLa cells show consistent positive staining

• Blocking and antibody incubation:

  • Block with 1-5% BSA or 5-10% normal serum in PBS for 1 hour

  • Use RPL19B antibody at 1:50-1:500 dilution (optimize per lot)

  • Incubate primary antibody overnight at 4°C

  • Secondary antibody recommendation: Alexa Fluor 488-conjugated anti-rabbit IgG

• Visualization and controls:

  • Expected pattern: Predominantly cytoplasmic with nucleolar enrichment

  • Counterstain nuclei with DAPI or Hoechst

  • Include both positive controls (HeLa cells) and negative controls (primary antibody omission)

How is RPL19B expression linked to cancer progression and what methodological approaches reveal this connection?

RPL19B expression shows significant correlation with cancer progression through several methodological approaches:

• mRNA expression analysis:

  • qPCR studies demonstrate that RPL19 mRNA levels are 4.9× higher in PC-3M prostate cancer cells compared to normal prostate epithelial (PNT2) cells

  • siRNA-mediated knockdown of RPL19 reduces expression to near-normal levels

• Protein expression in tissues:

  • Immunohistochemistry reveals elevated RPL19 protein in prostate cancer tissues

  • Western blotting confirms upregulation in cancer cell lines compared to normal controls

• Functional studies:

  • siRNA knockdown of RPL19 in PC-3M cells significantly reduces tumor growth in xenograft models

  • This effect appears selective rather than due to global protein synthesis disruption

• Mechanistic insights:

  • Gene expression array analysis reveals that RPL19 knockdown modulates specific subsets of genes

  • Networks affected include transcription factors and cellular adhesion genes

  • This suggests extra-ribosomal regulatory functions of RPL19

When interpreting RPL19B expression data in cancer research, consider:

• RPL19 may have context-dependent roles beyond ribosomal protein synthesis

• Genomic location (17q) is subject to amplifications and copy number changes in cancer

• Effects of RPL19 modulation appear to be selective rather than global

How do RPL19A and RPL19B paralogs functionally differ in yeast, and what experimental approaches demonstrate these differences?

Experimental approaches reveal distinct functional roles for RPL19A and RPL19B paralogs in yeast:

• Growth phenotype analysis:

  • Deletion of RPL19B (rpl19bΔ) inhibits growth on oleate-containing media

  • This suggests paralog-specific roles in lipid metabolism

• Translational profiling:

  • RPL19B deletion specifically affects translation of peroxisome-related proteins

  • This results in altered abundance of peroxisomal proteins and reduced peroxisome numbers

• BioID proximity labeling experiments:

  • Ribosomal proteins can be selectively biotinylated when proximal to peroxisomes

  • This approach tests whether paralog-specific ribosomes contribute to on-site translation

• mRNA 3'-UTR regulation:

  • The 3'-untranslated regions of yeast ribosomal protein mRNAs appear to have specialized functions

  • This contributes to paralog-specific roles in cellular processes

Though functionally distinct, RPL19B doesn't appear to contribute to peroxisome-localized translation in a paralog-specific manner, suggesting its role involves other regulatory mechanisms .

What strategies can address non-specific binding when using RPL19B antibodies?

When encountering non-specific binding with RPL19B antibodies, implement these methodological solutions:

• Antibody validation and selection:

  • Verify antibody specificity through knockdown/knockout controls

  • Consider using antibodies raised against different epitopes to confirm results

  • Antibodies targeting different regions (e.g., C-terminal vs. N-terminal) may exhibit different specificity profiles

• Optimized blocking protocols:

  • Increase blocking agent concentration (5-10% BSA or normal serum)

  • Extend blocking time to 2 hours at room temperature

  • Add 0.1-0.5% Tween-20 to blocking buffer to reduce hydrophobic interactions

• Antibody dilution optimization:

  • Perform titration experiments to determine optimal concentration

  • For Western blot: test 1:500, 1:1000, 1:2000, and 1:3000 dilutions

  • For IHC/IF: test 1:20, 1:50, 1:100, and 1:200 dilutions

• Additional washing steps:

  • Increase number of washes (5-6 washes of 5-10 minutes each)

  • Use higher detergent concentration in wash buffer (0.1-0.3% Tween-20)

  • Consider adding low salt (150-300 mM NaCl) to wash buffer to reduce ionic interactions

• Peptide competition assays:

  • Pre-incubate antibody with excess RPL19B immunogen peptide (10-100 fold molar excess)

  • Specific bands/staining should disappear while non-specific signals remain

  • This approach can confirm binding specificity and identify true signals

How can researchers differentiate between RPL19 paralogs when antibodies show cross-reactivity?

Differentiating between RPL19 paralogs requires specialized approaches:

• Genetic manipulation strategies:

  • Use paralog-specific knockouts or knockdowns (e.g., RPL19A deletion vs. RPL19B deletion in yeast)

  • Employ CRISPR-Cas9 to tag individual paralogs with distinct epitopes

  • These approaches allow functional differentiation even with cross-reactive antibodies

• Transcript-level analysis:

  • Employ RT-qPCR with paralog-specific primers targeting divergent regions

  • RNA-seq analysis can distinguish between paralogs based on unique sequences

  • These methods complement protein-level detection

• Mass spectrometry approaches:

  • Paralog-specific peptides can be identified by MS/MS analysis

  • Targeted proteomics (SRM/MRM) can quantify specific peptides unique to each paralog

  • This provides absolute quantification of each paralog

• Species-specific considerations:

  • In yeast models, use antibodies raised against specific yeast paralogs rather than mammalian RPL19

  • Validate specificity using paralog deletion strains as negative controls

• Epitope mapping:

  • Identify regions of sequence divergence between paralogs

  • Generate antibodies targeting these unique regions

  • Test specificity using recombinant proteins of each paralog

How can RPL19B antibodies be utilized in antibody-drug conjugate (ADC) development for targeted cancer therapy?

Utilizing RPL19B antibodies in ADC development requires sophisticated methodological approaches:

• Target validation methodology:

  • Confirm RPL19 overexpression in tumor vs. normal tissues using tissue microarrays

  • Quantify cell-surface expression using flow cytometry with non-permeabilized cells

  • Assess internalization rates with pH-sensitive fluorescent dyes conjugated to anti-RPL19B

• Antibody engineering considerations:

  • Humanize mouse monoclonal antibodies or develop fully human antibodies to reduce immunogenicity

  • Optimize binding affinity through directed evolution or affinity maturation

  • Introduce specific conjugation sites (e.g., engineered cysteines) for controlled drug attachment

• Conjugation chemistry strategies:

  • Select appropriate linkers based on desired release mechanisms:

    • Cleavable linkers (pH-sensitive, protease-sensitive) for active drug release

    • Non-cleavable linkers for sustained activity

  • Control drug-to-antibody ratio (DAR) to optimize efficacy and pharmacokinetics

• Payload selection methodology:

  • Marine-derived cytotoxins show particular promise for ADCs

  • Microtubule disruptors or DNA-damaging agents are commonly used

  • Match potency to expression level of RPL19 in target cells

• Preclinical validation approach:

  • Test internalization efficiency using confocal microscopy with labeled antibodies

  • Assess in vitro cytotoxicity against cell lines with varying RPL19 expression

  • Evaluate in vivo efficacy in xenograft models derived from RPL19-positive tumors

Given the elevated expression of RPL19 in certain cancers and evidence for its role in maintaining the malignant phenotype, RPL19B-targeted ADCs represent a promising therapeutic strategy .

What approaches can improve RPL19B antibody specificity for difficult-to-detect low-abundance epitopes?

Enhancing detection of low-abundance RPL19B epitopes requires advanced methodological refinements:

• Signal amplification technologies:

  • Tyramide signal amplification (TSA) can enhance sensitivity 10-100 fold for IHC/IF

  • Polymer-based detection systems offer improved sensitivity over traditional ABC methods

  • Quantum dots provide photostable, bright signals for long-term imaging

• Epitope retrieval optimization:

  • Compare multiple buffers systematically: citrate (pH 6.0), EDTA (pH 8.0), and Tris-EDTA (pH 9.0)

  • Test retrieval durations (10, 20, 30 minutes) to determine optimal conditions

  • Use pressure cooking vs. microwave methods to identify optimal heat transfer

• Antibody cocktail approach:

  • Combine multiple RPL19B antibodies targeting different epitopes

  • Use equal concentrations of each antibody to maintain batch consistency

  • This increases the probability of detecting low-abundance proteins

• Sample preparation refinements:

  • Implement phosphatase inhibitors alongside protease inhibitors in lysates

  • Use gentle fixation methods (0.5-2% paraformaldehyde) to preserve epitope accessibility

  • Consider native protein preservation for conformational epitopes

• Advanced microscopy techniques:

  • Employ structured illumination microscopy (SIM) for super-resolution imaging

  • Utilize confocal microscopy with spectral unmixing to separate autofluorescence

  • Apply deconvolution algorithms to enhance signal-to-noise ratio

• Proximity ligation assay (PLA):

  • This technique can detect single protein molecules through rolling circle amplification

  • Requires two antibodies binding adjacent epitopes on the target protein

  • Particularly useful for detecting low-abundance proteins in complex samples

How can researchers interpret conflicting data when RPL19B antibodies show divergent results across different experimental systems?

When faced with divergent results using RPL19B antibodies, apply this systematic interpretation framework:

• Antibody validation hierarchy:

  • Evaluate antibody validation data for each experimental system

  • Prioritize results from antibodies validated by knockout/knockdown controls

  • Consider cross-validation using antibodies from different suppliers or targeting different epitopes

• Technical variables analysis:

  • Create a detailed comparison table of experimental conditions:

    • Fixation methods and duration

    • Blocking reagents and times

    • Antibody concentration and incubation parameters

    • Detection systems and sensitivity

  • Identify methodological differences that could explain discrepancies

• Biological context evaluation:

  • Consider cell/tissue-specific post-translational modifications

  • Evaluate potential paralog expression differences between systems

  • Assess protein-protein interactions that might mask epitopes in specific contexts

• Statistical robustness assessment:

  • Determine if adequate replicates were performed

  • Compare quantification methods across studies

  • Consider power calculations to determine if sample sizes were sufficient

• Complementary technique approach:

  • Supplement antibody-based methods with non-antibody techniques:

    • RNA-seq or qPCR for transcript quantification

    • Mass spectrometry for protein identification and quantification

    • CRISPR-based tagging for direct visualization

• Isoform and splice variant consideration:

  • Check if antibodies target regions affected by alternative splicing

  • Sequence databases may reveal isoform differences between experimental systems

  • Design experiments to specifically detect potential variants

This systematic approach helps researchers interpret conflicting data as potentially revealing important biological differences rather than simply technical artifacts .